Serum programmed cell death proteins in amyotrophic lateral sclerosis

David R. Beers; Weihua Zhao; Jason R. Thonhoff; Alireza Faridar; Aaron D. Thome; Shixiang Wen; Jinghong Wang; Stanley H. Appel

doi:10.1016/j.bbih.2021.100209

Serum programmed cell death proteins in amyotrophic lateral sclerosis

David R. Beers, Weihua Zhao, Jason R. Thonhoff, Alireza Faridar, Aaron D. Thome, Shixiang Wen, Jinghong Wang, Stanley H. Appel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and its ligands, programmed cell death-ligand 1 and 2 (PD-L1/L2), leads to immune suppression. Serum soluble forms of these proteins, sPD-1/sPD-L1/sPD-L2, inhibit this suppression and promote pro-inflammatory responses. The purpose of this study was to determine if sPD-1, sPD-L1, and sPD-L2 were increased in sera of patients with ALS. sPD-1 and sPD-L2 were elevated in sera of patients and accurately reflected patients’ disease burdens. Increased sera levels of programmed cell death proteins reinforce the concept that peripheral pro-inflammatory responses contribute to systemic inflammation in patients with ALS.

Original language	English (US)
Article number	100209
Journal	Brain, behavior, & immunity - health
Volume	12
DOIs	https://doi.org/10.1016/j.bbih.2021.100209 https://doi.org/10.1016/j.bbih.2021.100209
State	Published - Mar 2021

Keywords

Amyotrophic lateral sclerosis
Cancer
Immune regulatory checkpoint pathways
Inflammation
Neurodegeneration
Neuromuscular disease
Program cell death proteins

ASJC Scopus subject areas

Nephrology

Access to Document

Cite this

@article{01c8dc0fa533420f84b1d0882210472f,

title = "Serum programmed cell death proteins in amyotrophic lateral sclerosis",

abstract = "Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and its ligands, programmed cell death-ligand 1 and 2 (PD-L1/L2), leads to immune suppression. Serum soluble forms of these proteins, sPD-1/sPD-L1/sPD-L2, inhibit this suppression and promote pro-inflammatory responses. The purpose of this study was to determine if sPD-1, sPD-L1, and sPD-L2 were increased in sera of patients with ALS. sPD-1 and sPD-L2 were elevated in sera of patients and accurately reflected patients{\textquoteright} disease burdens. Increased sera levels of programmed cell death proteins reinforce the concept that peripheral pro-inflammatory responses contribute to systemic inflammation in patients with ALS.",

keywords = "Amyotrophic lateral sclerosis, Cancer, Immune regulatory checkpoint pathways, Inflammation, Neurodegeneration, Neuromuscular disease, Program cell death proteins",

author = "Beers, {David R.} and Weihua Zhao and Thonhoff, {Jason R.} and Alireza Faridar and Thome, {Aaron D.} and Shixiang Wen and Jinghong Wang and Appel, {Stanley H.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = mar,

doi = "10.1016/j.bbih.2021.100209",

language = "English (US)",

volume = "12",

journal = "Brain, behavior, & immunity - health",

issn = "2666-3546",

publisher = "Elsevier",

}

TY - JOUR

T1 - Serum programmed cell death proteins in amyotrophic lateral sclerosis

AU - Beers, David R.

AU - Zhao, Weihua

AU - Thonhoff, Jason R.

AU - Faridar, Alireza

AU - Thome, Aaron D.

AU - Wen, Shixiang

AU - Wang, Jinghong

AU - Appel, Stanley H.

PY - 2021/3

Y1 - 2021/3

N2 - Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and its ligands, programmed cell death-ligand 1 and 2 (PD-L1/L2), leads to immune suppression. Serum soluble forms of these proteins, sPD-1/sPD-L1/sPD-L2, inhibit this suppression and promote pro-inflammatory responses. The purpose of this study was to determine if sPD-1, sPD-L1, and sPD-L2 were increased in sera of patients with ALS. sPD-1 and sPD-L2 were elevated in sera of patients and accurately reflected patients’ disease burdens. Increased sera levels of programmed cell death proteins reinforce the concept that peripheral pro-inflammatory responses contribute to systemic inflammation in patients with ALS.

AB - Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder. Activation of programmed cell death-1 (PD-1), and its ligands, programmed cell death-ligand 1 and 2 (PD-L1/L2), leads to immune suppression. Serum soluble forms of these proteins, sPD-1/sPD-L1/sPD-L2, inhibit this suppression and promote pro-inflammatory responses. The purpose of this study was to determine if sPD-1, sPD-L1, and sPD-L2 were increased in sera of patients with ALS. sPD-1 and sPD-L2 were elevated in sera of patients and accurately reflected patients’ disease burdens. Increased sera levels of programmed cell death proteins reinforce the concept that peripheral pro-inflammatory responses contribute to systemic inflammation in patients with ALS.

KW - Amyotrophic lateral sclerosis

KW - Cancer

KW - Immune regulatory checkpoint pathways

KW - Inflammation

KW - Neurodegeneration

KW - Neuromuscular disease

KW - Program cell death proteins

UR - http://www.scopus.com/inward/record.url?scp=85122283779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122283779&partnerID=8YFLogxK

U2 - 10.1016/j.bbih.2021.100209

DO - 10.1016/j.bbih.2021.100209

M3 - Article

C2 - 34589734

SN - 2666-3546

VL - 12

JO - Brain, behavior, & immunity - health

JF - Brain, behavior, & immunity - health

M1 - 100209

ER -

Serum programmed cell death proteins in amyotrophic lateral sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this